Sublingual Immunotherapy in Allergic Rhinitis and Asthma: A Review of Recent Clinical Evidence

K. Erny-Albrecht,W. Valentine,J. Christensen,U. Vestenbaek,A. Palmer
2007-04-26
Abstract:A growing body of evidence is accumulating in support of sublingual immunotherapy (SLIT) for the treatment of allergic rhinitis and asthma. Several European countries use SLIT in preference to the more established subcutaneous immunotherapy (SCIT) because of improved safety and ease of administration, particularly among children and those with asthma. However uncertainty persists, particularly in the United States where SCIT is widely accepted and utilized, and SLIT is still subject to review. Contributing to this uncertainty is the apparent between-trial heterogeneity regarding efficacy; a lack of understanding regarding the mechanism of action; failure to define optimal allergen doses; and, until recently, the lack of evidence demonstrating satisfactory patient compliance with this homebased treatment. In the following review we look at
What problem does this paper attempt to address?